KHC-4 inhibits β-catenin expression in prostate cancer cells

Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission
C-Y HuangC-H Shen

Abstract

KHC-4 is a 2-phenyl-4-quinolone analogue that exhibits anticancer activity. Aberrant activation of β-catenin signaling contributes to prostate cancer development and progression. Therefore, targeting β-catenin expression could be a useful approach to treating prostate cancer. We found that KHC-4 can inhibit β-catenin expression and its signaling pathway in DU145 prostate cancer cells. Treatment with KHC-4 decreased total β-catenin expression and concomitantly decreased β-catenin levels in both the cytoplasm and nucleus of cells. KHC-4 treatment also inhibited β-catenin expression and that of its target proteins, PI3K, AKT, GSK3β and TBX3. We monitored the stability of β-catenin with the proteasomal inhibitor, MG132, in DU145 cells and found that MG132 reversed KHC-4-induced proteasomal β-catenin degradation. We verified CDK1/β-catenin expression in KHC-4 treated DU145 cells. We found that roscovitine treatment reversed cell proliferation by arresting the cell cycle at the G2/M phase and β-catenin expression caused by KHC-4 treatment. We suggest that KHC-4 inhibits β-catenin signaling in DU145 prostate cancer cells.

References

Jul 30, 1999·Biochemical and Biophysical Research Communications·S Hiscox, W G Jiang
Jan 31, 2002·World Journal of Gastroenterology : WJG·J CuiM H Zile
Feb 13, 2002·The American Journal of Pathology·Newton Alexander Chiang Shuek Wong, Massimo Pignatelli
Oct 12, 2004·Annual Review of Cell and Developmental Biology·Catriona Y Logan, Roel Nusse
Mar 16, 2005·Nature Structural & Molecular Biology·Danette L Daniels, William I Weis
Nov 23, 2005·Urologic Oncology·Meena JaggiK C Balaji
Dec 22, 2005·Frontiers in Bioscience : a Journal and Virtual Library·Han Chu LeeJack R Wands
Jan 31, 2008·Neoplasia : an International Journal for Oncology Research·Enrico De SmaeleAlberto Gulino
Feb 10, 2009·Nature Clinical Practice. Urology·William P HarrisBruce Montgomery
Jul 22, 2009·Developmental Cell·Bryan T MacDonaldXi He
Mar 5, 2010·Journal of Dental Research·F Liu, S E Millar
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Apr 25, 2012·Prostate Cancer·Teresa Maria Santos AmaralLuis Costa
Aug 30, 2012·The American Journal of Chinese Medicine·Jin-Ming HwangChih-Yang Huang
Jul 19, 2013·Development·Shuhui Lim, Philipp Kaldis
Apr 4, 2014·The Chinese Journal of Physiology·Tien-Huang LinChih-Yang Huang
Aug 26, 2015·Environmental Toxicology·Cheng-Huang ShenChih-Yang Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adherens Junctions

An adherens junction is defined as a cell junction whose cytoplasmic face is linked to the actin cytoskeleton. They can appear as bands encircling the cell (zonula adherens) or as spots of attachment to the extracellular matrix (adhesion plaques). Adherens junctions uniquely disassemble in uterine epithelial cells to allow the blastocyst to penetrate between epithelial cells. Discover the latest research on adherens junctions here.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.